Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People whose general physical fitness is rated at 0 or 1 on a standard oncology performance scale, meaning they are fully active or have only minor limitations on physical activity.
• People who have at least one tumour that can be measured on a scan.
• People whose side effects from any previous cancer treatments or surgery have mostly resolved to mild or no symptoms.
• People whose organs (such as liver and kidneys) and bone marrow are functioning well enough to meet the trial's requirements (confirm specific thresholds with trial site).
• People expected to survive for at least 12 weeks.
• People who have been diagnosed with pancreatic cancer (specifically ductal adenocarcinoma or adenocarcinoma) that has spread or cannot be surgically removed.
• People who have not previously received any systemic (whole-body) treatment for unresectable locally advanced or metastatic pancreatic cancer.
• People who agree to use at least one medically approved form of contraception during the trial and for at least 6 months after the last dose of trial drug, or 9 months after the last dose of the chemotherapy drug oxaliplatin, whichever is later. Women who are able to become pregnant must have a negative pregnancy test within 3 days before starting the study medication and must not be breastfeeding.
• People who have given their written informed consent to participate.

Who may not be able to join:

• People whose pancreatic cancer has a specific genetic feature known as high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR).
• People with active cancer that has spread to the brain or spinal cord and is causing symptoms or continuing to grow.
• People who, within 14 days before enrolment, still have uncontrolled fluid build-up around the lungs or in the abdomen despite treatment, or who have fluid around the heart causing symptoms.
• People who have an unresolved bile duct blockage within 14 days before enrolment, or whose condition has been stable for less than 14 days after having a bile duct stent placed.
• People who have lost more than 20% of their body weight in the 2 months before enrolment, or whose body mass index (BMI) is below 18 kg/m².
• People who have previously been treated with certain specific types of antibody drugs that target immune regulatory cells (CCR8 antibodies, CTLA-4 antibodies, or similar drugs).
• People who have had major surgery within 28 days before enrolment.
• People who have used immune-suppressing medications within 14 days before enrolment.
• People who have received a live attenuated vaccine within 28 days before enrolment, or who plan to receive one during the trial or within 60 days after finishing the study treatment.
• People who have received any anti-cancer treatment (including chemotherapy, radiotherapy, immunotherapy, or other cancer therapies) within 28 days before enrolment.
• People who have been diagnosed with any other cancer within the past 5 years.
• People who have any active, known, or suspected autoimmune disease.
• People who have had significant bleeding or a known tendency to bleed within 3 months before enrolment, or who have had a blood clot in an artery or vein within 6 months before enrolment.
• People who have had a serious blood vessel condition within 6 months before enrolment.
• People with serious wounds that have not healed, active ulcers, or untreated broken bones.
• People who have nerve damage in their hands or feet rated above mild (grade 1).
• People who have had a hole or abnormal opening form in their digestive tract within 6 months before enrolment.
• People who have had signs or symptoms of a bowel blockage within 6 months before enrolment.
• People who have interstitial lung disease, a history of non-infectious lung inflammation, or other serious uncontrolled conditions affecting the whole body.
• People who are known to be allergic to the study drug or any of its ingredients, or who have had a severe allergic reaction to other monoclonal antibody treatments.
• People with HIV infection or AIDS, or who have untreated active hepatitis B or C, or both hepatitis B and C at the same time.
• People with heart-related conditions or symptoms that are not well controlled (confirm specific details with trial site).
• People who have needed antibiotics for 7 or more days within the 28 days before enrolment, or who have an unexplained fever above 38.5°C at the time of screening.
• People who have had an organ transplant or bone marrow/stem cell transplant from another person.
• People who have taken part in another clinical drug trial within 4 weeks before enrolment, or where enough time has not passed since their last experimental medication.
• People with a known history of misuse of psychotropic substances or drugs.
• People with other serious physical or mental health conditions, or abnormal test results, that the trial doctor considers would make participation unsafe or affect the trial results.

Important: Always verify eligibility with the trial site directly before applying.